Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Shashank Sinha

Advanced Heart Failure · Inova Fairfax Hospital

View

Dr. Javed Butler

Advanced Heart Failure · Baylor Health Care System

View

Dr. Andrew Sauer

Advanced Heart Failure · Saint Luke's

View

Dr. Anu Lala

Advanced Heart Failure · Mount Sinai

View

Dr. Robert Mentz

Advanced Heart Failure · Duke University

View

Dr. Sunny Varshney

Advanced Heart Failure · Stanford

View

Dr. Stephanie Hsiao

Advanced Heart Failure · Stanford

View

Dr. Michelle Kittleson

Advanced Heart Failure · Cedars-Sinai

View

Dr. Adrian Hernandez

Advanced Heart Failure · Duke

View

Dr. Dorairaj Prabhakaran

General Cardiology

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Heart Failure Devices: Treatment Options, Underutilization, and a Proposed Trigger System for Patient Referral and Evaluation.

    Sep 26, 2025DOI: 10.1016/j.cardfail.2025.08.019Journal ArticleJCF

    Written by: Marat FudimDmitry M YaranovRicha GuptaLaurie LetarteSamuel F SearsBrian G HowardNir UrielVikram RajeKiran MahmoodSean P PinneyAmin YehyaAmit AlamPujan PatelAlbert HicksAmarinder BindraSteve M AntoineJason FelibertiAllman RollinsVishal N RaoPatrick McCannNirav RavalRachel A GarciaAhmed Sayed

    Find these authors on Roon

    AB
    Dr. Amarinder Bindra
    Advanced Heart Failure · BUMC

    Summary

    The use of guideline-directed medical therapy (GDMT) has substantially prolonged and improved the lives of patients with heart failure (HF). Nevertheless, adherence rates remain suboptimal. Even when successfully maximized and adhered to, there is a substantial residual risk of recurrent HF hospitalization and death. In light of this, there is a strong need for effective interventions that can decrease the high residual risk seen in patients with HF. Several device options exist that are approved by the US Food and Drug Administration and that have been shown to decrease morbidity and/or mortality in patients among whom GDMT is maximized. These strategies include valvular interventions (aortic valve replacement, mitral valve repair, and tricuspid valve repair or replacement), cardiac resynchronization, cardiac contractility modulation, remote hemodynamic monitoring, and baroreceptor activation therapy. The pivotal trials for each of these interventions, and the patient populations for which they have been approved, are discussed. Current rates of device use in clinical practice remain very low. For many device classes, the vast majority of eligible patients are not offered or prescribed the device. Several reasons may explain this mismatch, foremost of which is a lack of clinical awareness about when to escalate therapy, how to identify patients requiring more than GDMT, and access to centers with sufficient experience. To aid the appropriate uptake of device therapy in clinical practice, we propose a simple mnemonic for use by clinicians that can prompt the early identification and prompt referral of patients with HF who likely merit consideration of additional device-based therapy in addition to GDMT.
    ABDr. Amarinder Bindra

    Dr. Amarinder Bindra

    Cardiology · Advanced Heart Failure & Transplantation
    Baylor University Medical Center
    amarinder